DiscGenics Raises $50 Million in Series C Funding

By Mike Evers

DiscGenics Raises $50 Million in Series C Funding

DiscGenics announced it has raised $50 million in Series C funding led by Ci:z Investment LLP with participation from new investors including Eagle Fund SP1 LLP, Medical Incubator Japan and CareNet of Japan. This round of funding brings the company to just over $71 million to-date.

Discgenics will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease, fund future commercialization efforts in the U.S. and Japan as well as scale its allogeneic cell manufacturing facility in Salt Lake City, Utah.

Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Funding